Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Olga P. Nyssen
  • Ángeles Pérez-Aisa
  • Bojan Tepes
  • Luis Rodrigo-Sáez
  • Pilar M. Romero
  • Alfredo Lucendo
  • Manuel Castro-Fernández
  • Perminder Phull
  • Jesús Barrio
  • Luis Bujanda
  • Juan Ortuño
  • Miguel Areia
  • Natasa Brglez Jurecic
  • José María Huguet
  • Noelia Alcaide
  • Irina Voynovan
  • José María Botargues Bote
  • Inés Modolell
  • Jorge Pérez Lasala
  • Inés Ariño
  • Laimas Jonaitis
  • Manuel Dominguez-Cajal
  • György Buzas
  • Frode Lerang
  • Monica Perona
  • Dmitry Bordin
  • Toni Axon
  • Antonio Gasbarrini
  • Ricardo Marcos Pinto
  • Yaron Niv
  • Limas Kupcinskas
  • Ante Tonkic
  • Marcis Leja
  • Theodore Rokkas
  • Lyudmila Boyanova
  • Oleg Shvets
  • Marino Venerito
  • Bytzer, Peter
  • Adrian Goldis
  • Ilkay Simsek
  • Vincent Lamy
  • Krzysztof Przytulski
  • Lumír Kunovský
  • Lisette Capelle
  • Tomica Milosavljevic
  • María Caldas
  • Ana Garre
  • Francis Mégraud
  • Colm O'Morain
  • Javier P. Gisbert
  • the Hp-EuReg Investigators

Background: Experience in Helicobacter pylori eradication treatment of patients allergic to penicillin is very scarce. A triple combination with a PPI, clarithromycin (C), and metronidazole (M) is often prescribed as the first option, although more recently the use of a quadruple therapy with PPI, bismuth (B), tetracycline (T), and M has been recommended. Aim: To evaluate the efficacy and safety of first-line and rescue treatments in patients allergic to penicillin in the “European Registry of H pylori management” (Hp-EuReg). Methods: A systematic prospective registry of the clinical practice of European gastroenterologists (27 countries, 300 investigators) on the management of H pylori infection. An e-CRF was created on AEG-REDCap. Patients with penicillin allergy were analyzed until June 2019. Results: One-thousand eighty-four patients allergic to penicillin were analyzed. The most frequently prescribed first-line treatments were as follows: PPI + C + M (n = 285) and PPI + B + T + M (classic or Pylera®; n = 250). In first line, the efficacy of PPI + C + M was 69%, while PPI + B + T + M reached 91% (P <.001). In second line, after the failure of PPI + C + M, two rescue options showed similar efficacy: PPI + B + T + M (78%) and PPI + C + levofloxacin (L) (71%) (P >.05). In third line, after the failure of PPI + C + M and PPI + C + L, PPI + B + T + M was successful in 75% of cases. Conclusion: In patients allergic to penicillin, a triple combination with PPI + C + M should not be generally recommended as a first-line treatment, while a quadruple regimen with PPI + B + T + M seems to be a better option. As a rescue treatment, this quadruple regimen (if not previously prescribed) or a triple regimen with PPI + C + L could be used but achieved suboptimal (<80%) results.

OriginalsprogEngelsk
Artikelnummere12686
TidsskriftHelicobacter
Vol/bind25
Udgave nummer3
Antal sider11
ISSN1083-4389
DOI
StatusUdgivet - 2020

Bibliografisk note

Funding Information:
Dr Gisbert has served as a speaker, a consultant, and advisory member for or has received research funding from Casen Recordati, Mayoly, Allergan, Advia, Diasorin. Dr P. Nyssen has received research funding from Allergan.

Publisher Copyright:
© 2020 John Wiley & Sons Ltd

ID: 270550826